Que Liu

Title: Que Liu: Innovator in Pharmaceutical Treatments

Introduction

Que Liu is a prominent inventor based in San Diego, CA, known for his contributions to the field of pharmaceuticals. He holds 2 patents that focus on innovative treatments for serious health conditions. His work has significantly impacted the medical community, particularly in the areas of liver disease and cardiac health.

Latest Patents

Liu's latest patents include groundbreaking methods for the treatment of primary biliary cholangitis (PBC). One of his notable inventions involves the use of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, also known as Compound 1. This compound is utilized in combination with various other medications to enhance treatment efficacy. Additionally, Liu has developed methods using cardioprotective incretin compounds (CICs) such as GLP-1 and exendin to prevent cardiac remodeling and reduce the risk of congestive heart failure.

Career Highlights

Throughout his career, Que Liu has worked with notable companies in the pharmaceutical industry, including Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His experience in these organizations has allowed him to refine his expertise and contribute to significant advancements in medical treatments.

Collaborations

Liu has collaborated with esteemed colleagues such as Christen M Anderson and Cheryl Geraldine Lassen. These partnerships have fostered a collaborative environment that encourages innovation and the development of effective therapeutic solutions.

Conclusion

Que Liu's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through research and invention. His patents reflect a deep understanding of complex medical conditions and a dedication to finding effective treatments.